Log in to save to my catalogue

Alzheimer's disease staging with [18F]MK6240 and [18F]Flortaucipir ‐ the HEAD study

Alzheimer's disease staging with [18F]MK6240 and [18F]Flortaucipir ‐ the HEAD study

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11714529

Alzheimer's disease staging with [18F]MK6240 and [18F]Flortaucipir ‐ the HEAD study

Publication information

Publisher

Hoboken: John Wiley and Sons Inc

Subjects

Subjects and topics

More information

Scope and Contents

Contents

Background
Utilizing PET amyloid‐beta (Aβ) and tau for staging Alzheimer’s Disease (AD) has demonstrated potential in identifying individuals with varying degrees of disease severity, applicable to both clinical trials and practice. However, the diverse binding characteristics of tau tracers pose challenges to the application of this staging acr...

Alternative Titles

Full title

Alzheimer's disease staging with [18F]MK6240 and [18F]Flortaucipir ‐ the HEAD study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11714529

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11714529

Other Identifiers

ISSN

1552-5260

E-ISSN

1552-5279

DOI

10.1002/alz.091820

How to access this item